News >

Expert Explains Treatment Approaches for MCL

Brandon Scalea
Published: Thursday, Nov 15, 2018

Simon Rule, MD
Simon Rule, MD, PhD
For young, fit patients with mantle cell lymphoma (MCL), the best frontline treatment approach could be observation, according to Simon Rule, MD, PhD.

Rule discussed the observational and active therapeutic approaches for patients with MCL.

OncLive: What is the current management for patients with MCL?

Rule: For younger patients, it is pretty well established that it is a high-dose cytarabine-based regimen. It is usually followed by a stem cell transplant, followed by rituximab maintenance. That is pretty much the standard. There are a number of different ways you can give high-dose cytarabine. 

What regimens are in development?

Of course, the drugs that have made the biggest impact in this disease are the BTK inhibitors. The question is if we need these drugs for the frontline treatment of younger patients. These patients are off drugs and living a normal quality of life. When they relapse—because everyone relapses—that is when we introduce these novel therapies.

There are a number of ongoing studies in the United Kingdom that are going to challenge the traditional paradigm. Specifically, do we need transplant? That is something for the future. It is difficult in the younger patients to use anything other than the traditional chemotherapy. When I give presentations about this disease, I always say, "Don't forget that chemotherapy works." There is a lot of excitement about new drugs, obviously. However, the odd thing about these drugs is that they will probably be more valuable for the older, frailer patients. Be cautious about using new drugs early. 

Please explain the watch and wait approach.

I have been watching and waiting MCL for a long time—over a decade. People thought I was mad when I first started doing it, and now it is becoming pretty well established. Watching and waiting does not disadvantage patients. If they are asymptomatic with low-volume disease, there is no benefit in treating someone early in treatment if they are in good health. It sounds counterintuitive with an aggressive cancer, but the answer is that when you treat this disease, it inevitably relapses. When it relapses, it is a much more difficult disease to treat. You won't know if someone has indolent disease unless you leave them alone.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication